» Articles » PMID: 34802051

Once Weekly Selinexor, Carfilzomib and Dexamethasone in Carfilzomib Non-refractory Multiple Myeloma Patients

Abstract

Background: Proteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM).

Methods: The safety, efficacy, maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D) of selinexor (80 or 100 mg) + carfilzomib (56 or 70 mg/m) + dexamethasone (40 mg) (XKd) once weekly (QW) was evaluated in patients with relapsed refractory MM (RRMM) not refractory to carfilzomib.

Results: Thirty-two patients, median prior therapies 4 (range, 1-8), were enrolled. MM was triple-class refractory in 38% of patients and 53% of patients had high-risk cytogenetics del(17p), t(4;14), t(14;16) and/or gain 1q. Common treatment-related adverse events (all/Grade 3) were thrombocytopenia 72%/47% (G3 and G4), nausea 72%/6%, anaemia 53%/19% and fatigue 53%/9%, all expected and manageable with supportive care and dose modifications. MTD and RP2D were identified as selinexor 80 mg, carfilzomib 56 mg/m, and dexamethasone 40 mg, all QW. The overall response rate was 78% including 14 (44%) ≥ very good partial responses. Median progression-free survival was 15 months.

Conclusions: Weekly XKd is highly effective and well-tolerated. These data support further investigation of XKd in patients with MM.

Citing Articles

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review.

Tan C, Kacerek D, Kampirapawong N, Godara A, Chaiyakunapruk N Cancer Med. 2025; 14(5):e70585.

PMID: 40052837 PMC: 11887125. DOI: 10.1002/cam4.70585.


International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.

Costa L, Banerjee R, Mian H, Weisel K, Bal S, Derman B Leukemia. 2025; 39(3):543-554.

PMID: 39870767 PMC: 11879857. DOI: 10.1038/s41375-024-02482-6.


Novel-and Not So Novel-Inhibitors of the Multifunctional CRM1 Protein.

Aumann W, Kazi R, Harrington A, Wechsler D Oncol Rev. 2024; 18:1427497.

PMID: 39161560 PMC: 11330842. DOI: 10.3389/or.2024.1427497.


Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review.

Schutt J, Brinkert K, Plis A, Schenk T, Brioli A Cancer Drug Resist. 2024; 7:26.

PMID: 39050883 PMC: 11267153. DOI: 10.20517/cdr.2024.39.


Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

White D, Schiller G, Madan S, Lentzsch S, Chubar E, Lavi N Front Oncol. 2024; 14:1352281.

PMID: 38826786 PMC: 11140414. DOI: 10.3389/fonc.2024.1352281.


References
1.
Kashyap T, Argueta C, Aboukameel A, Unger T, Klebanov B, Mohammad R . Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 2016; 7(48):78883-78895. PMC: 5346685. DOI: 10.18632/oncotarget.12428. View

2.
Shah J, Stadtmauer E, Abonour R, Cohen A, Bensinger W, Gasparetto C . Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015; 126(20):2284-90. PMC: 4643003. DOI: 10.1182/blood-2015-05-643320. View

3.
Shuster J . Median follow-up in clinical trials. J Clin Oncol. 1991; 9(1):191-2. DOI: 10.1200/JCO.1991.9.1.191. View

4.
Turner J, Dawson J, Emmons M, Cubitt C, Kauffman M, Shacham S . CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo. J Cancer. 2013; 4(8):614-25. PMC: 3805989. DOI: 10.7150/jca.7080. View

5.
Dimopoulos M, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R . Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2015; 17(1):27-38. DOI: 10.1016/S1470-2045(15)00464-7. View